Covalent binding of a fluorinated 2-nitroimidazole to EMT-6 tumors in Balb/C mice: detection by F-19 nuclear magnetic resonance at 2.35 T

Int J Radiat Oncol Biol Phys. 1986 Jul;12(7):1243-5. doi: 10.1016/0360-3016(86)90268-3.

Abstract

A hexafluorinated 2-nitroimidazole (CCI-103F) has been synthesized and its properties as a hypoxic cell binder investigated. The drug has a plasma half-life of 90 min in Balb/C mice and a tumor-to-plasma ratio of 0.8. Following sustained exposure to the drug and a washout period for the unbound drug, liver and tumor samples were excised. NMR investigation of the excised tissue in a 2.35 T animal sized NMR facility revealed the presence of 19F bound to both tissues. Further improvement in sensitivity is required to make 19F NMR detection of binding in situ feasible.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Magnetic Resonance Spectroscopy*
  • Mice
  • Mice, Inbred BALB C
  • Neoplasm Transplantation
  • Neoplasms, Experimental / metabolism*
  • Nitroimidazoles / metabolism*
  • Oxygen / physiology

Substances

  • Nitroimidazoles
  • CCI 103F
  • Oxygen